Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Compounding Restrictions Could Create New Headaches For FDA

Executive Summary

Advisory committee votes to add oxycodone to do-not-compound list, but will compounders now begin producing abuse-deterrent formulations?

You may also be interested in...



FDA Forced To Update Approved Products List In Do-Not-Compound Review

ANDAs mistakenly still are cataloged as approved even though they have been withdrawn from marketing.

OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting

There will be no generics of original OxyContin; FDA says it can no longer serve as a reference product because it has a greater abuse potential than the reformulation, where Purdue has secured particularly strong language regarding reducing intranasal abuse.

Opioid Abuse-Deterrent Labeling Claim Decision By FDA Could Come Soon

Purdue epidemiological studies indicate reformulation of OxyContin had a positive effect on abuse and misuse of the drug, but the company says continued monitoring is needed to assess whether the positive trend continues.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel